eli lilly glp-1 agonist is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Novo Nordisk, Eli Lilly roll
Description
Nothing to be concerned about it seems
The estimated half-life of tizepatide is approximately 116 h, supporting its once-weekly subcutaneous administration
In addition to serious side effects like stomach paralysis and intestinal blockages, blindness is now a concern
GLP-1 agonists are typically initiated at low doses and gradually increased according to manufacturer guidelines, which helps minimise gastrointestinal side effects and may moderate the pace of weight reduction
Liraglutide drug monograph, BNF
This kind of optionality may provide incremental long-term strategic value if the regulatory landscape surrounding psychedelic-based therapies continues to evolve
